Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

ABSTRACT:

Aims

Spironolactone is widely used to treat heart failure, hypertension and liver disease with increased usage in recent years. Spironolactone has endocrine effects that could influence cancer risks and historical reports suggest possible links with increased risk of certain types of cancer. The aim of this study was to assess the effect of spironolactone exposure on cancer incidence.

Methods

A pharmacoepidemiological propensity score-matched cohort study was performed to assess the effect of spironolactone exposure on cancer incidence. Cox proportional hazards models were used to analyse time to first diagnosis of each prespecified cancer and hazard ratios for spironolactone exposure are presented. The setting for the study was UK primary care using the Clinical Practice Re

SUBMITTER: Mackenzie IS 

PROVIDER: S-EPMC5306481 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature